share_log

Reported Earlier, Senseonics Reports $22.5M Preliminary 2024 Revenue With $8.4M In Q4, 56% YoY Patient Growth, And Milestone Eversense 365 Launch Success

Benzinga ·  Jan 9 15:38

Recent Highlights & Accomplishments

  • Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024 total revenue of approximately $22.5 million
  • Received FDA approval for Eversense 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia.
  • Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients
  • Reached a milestone of over a 1,000 annual U.S. Eversense prescribers during 2024
  • Continued strong interest in Eversense 365, as evidenced by the following early U.S. launch performance indicators:
    • Direct to Consumer (DTC) leads have doubled in Q4 compared to the pre-launch third quarter
    • New patient shipments of approximately 600 in December were the highest monthly total in the Company's history
    • The number of patients switching to Eversense from competitive CGM's has increased 49% since Eversense 365 launch
    • 118% increase in patient referrals from physicians since launch
  • Following recent appreciation in Company's share price, determined not to proceed with previously announced Special Meeting of stockholders to consider reverse stock split.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment